Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

Authors: Radboud J. Duintjer Tebbens, Mark A. Pallansch, Kimberly M. Thompson

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) following infection with oral poliovirus vaccine (OPV). These individuals pose a risk of live poliovirus reintroduction into the population after global wild poliovirus eradication and subsequent OPV cessation. Treatment with polio antiviral drugs may potentially stop excretion in some of these individuals and thus may reduce the future population risk.

Methods

We developed a discrete event simulation model to characterize the global prevalence of long-term iVDPV excretors based on the best available evidence. We explored the impact of different assumptions about the effectiveness of polio antiviral drugs and the fraction of long-term excretors identified and treated.

Results

Due to the rarity of long-term iVDPV excretion and limited data on the survival of PID patients in developing countries, uncertainty remains about the current and future prevalence of long-term iVDPV excretors. While the model suggests only approximately 30 current excretors globally and a rapid decrease after OPV cessation, most of these excrete asymptomatically and remain undetected. The possibility that one or more PID patients may continue to excrete iVDPVs for several years after OPV cessation represents a risk for reintroduction of live polioviruses after OPV cessation, particularly for middle-income countries. With the effectiveness of a single polio antiviral drug possibly as low as 40 % and no system in place to identify and treat asymptomatic excretors, the impact of passive use of a single polio antiviral drug to treat identified excretors appears limited. Higher drug effectiveness and active efforts to identify long-term excretors will dramatically increase the benefits of polio antiviral drugs.

Conclusions

Efforts to develop a second polio antiviral compound to increase polio antiviral effectiveness and/or to maximize the identification and treatment of affected individuals represent important risk management opportunities for the polio endgame. Better data on the survival of PID patients in developing countries and more longitudinal data on their exposure to and recovery from OPV infections would improve our understanding of the risks associated with iVDPV excretors and the benefits of further investments in polio antiviral drugs.
Literature
1.
World Health Organization: Polio Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) use after Global Polio Eradication. Framework for National Policy Makers in OPV-using Countries. Geneva, 2005; Report No.: WHO/POL/05.02.
2.
Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26(6):1471–505.CrossRef
3.
World Health Organization. Transmission of wild poliovirus type 2—Apparent global interruption. Wkly Epidemiol Rec. 2001;76:95–7.
4.
World Health Organization: Global Polio Eradication Initiative: Polio Eradication and Endgame Strategic Plan (2013–2018). Geneva, 2013; Report No.: WHO/POLIO/13.02.
5.
6.
Dowdle WR, van der Avoort HGAM, de Gourville EM, Delpeyroux F, Deshpande JM, Hovi T, et al. Containment of polioviruses after eradication: characterizing risk to improve management. Risk Anal. 2006;26(6):1449–69.CrossRefPubMed
7.
Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S475–84.CrossRefPubMed
8.
Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Expert review on poliovirus immunity and transmission. Risk Anal. 2013;33(4):544–605.CrossRefPubMed
9.
Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Anal. 2013;33(4):606–46.CrossRefPubMed
10.
Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Exp Rev Vaccines. 2014;13(2):221–34.CrossRef
11.
Anis E, Kopel E, Singer S, Kaliner E, Moerman L, Moran-Gilad J, Sofer D, Manor Y, Shulman L, Mendelson E et al.. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill. 2013, 18(38).
12.
Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SGF, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800–12.CrossRefPubMed
13.
Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis. 2014;210 Suppl 1:S485–97.CrossRefPubMed
14.
National Research Council. Exploring the role of antiviral drugs in the eradication of polio: Workshop report. Washington, D.C: National Academy Press; 2006.
15.
McKinlay MA, Collett MS, Hincks JM, Oberste MS, Pallansch MA, Okayasu H, et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis. 2014;210 Suppl 1:S447–53. in press.CrossRefPubMed
16.
Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenla M, da Silva EE, Kahn AA, et al. Search for polio virus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil and the United Kingdom. Bull World Health Organ. 2004;82(1):3–8.PubMedPubMedCentral
17.
Fiore L, Plebani A, Buttinelli G, Fiore S, Donati V, Marturano J, et al. Search for poliovirus long-term excretors among patients affected by agammaglobulinemia. Clin Immunol. 2004;111(1):98–102.CrossRefPubMed
18.
Burns C, Diop O, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210 Suppl 1:S283–93.CrossRefPubMed
19.
Driss N, Ben-Mustapha I, Mellouli F, Ben Yahia A, Touzi H, Bejaoui M, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol. 2012;19(10):1684–9.CrossRefPubMedPubMedCentral
20.
de Silva R, Gunasena S, Ratnayake D, Wickremesinghe GD, Kumarasiri CD, Pushpakumara BA, et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine. 2012;30(52):7561–5.CrossRefPubMed
21.
Galal NM, Bassiouny L, Nasr E, Abdelmeguid N. Isolation of poliovirus shedding following vaccination in children with antibody deficiency disorders. J Infect Dev Ctries. 2012;6(12):881–5.CrossRefPubMed
22.
Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Rev Vaccines. 2012;11(4):449–59.CrossRefPubMed
23.
Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Thompson KM: An economic analysis of poliovirus risk management policy options for 2013–2052 (submitted to BMC ID). doi:10.​1186/​s12879-015-1112-8
24.
Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal. 2013;23(4):703–49.CrossRef
25.
Alexander Jr JP, Gary Jr HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis. 1997;175 Suppl 1:S176–82.CrossRefPubMed
26.
MacCallum FO. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec Rep Ser Med Res Counc (G B). 1971;310:72–85.
27.
Martín J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol. 2000;74(7):3001–10.CrossRefPubMedPubMedCentral
28.
Hara M, Saito Y, Komatsu T, Kodama H, Abo W, Chiba S, et al. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol Immunol. 1981;25(9):905–13.CrossRefPubMed
29.
Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals. 2006;34(2):117–22.CrossRefPubMed
30.
Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36(10):2893–9.PubMedPubMedCentral
31.
Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235–42.CrossRefPubMed
32.
Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology. 1999;265(2):178–84.CrossRefPubMed
33.
MacLennan CA, Dunn G, Wood P. Chronic infection with vaccine-derived poliovirus in a common variable immunodeficiency and implications for world health. J Allergy Clin Immunol. 2001;107(Suppl):S304–5.
34.
DeVries AS, Harper J, Murray A, Lexau C, Bahta L, Christensen J, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med. 2011;364(24):2316–23.CrossRefPubMed
35.
Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009-March. MMWR Morb Mortal Wkly Rep 2011. 2011;60(25):846–50.
36.
Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol. 2009;157 Suppl 1:3–11.CrossRefPubMedPubMedCentral
37.
Mohammadinejad P, Aghamohammadi A, Abolhassani H, Sadaghiani MS, Abdollahzade S, Sadeghi B, et al. Pediatric patients with common variable immunodeficiency: long-term follow-up. J Investig Allergol Clin Immunol. 2012;22(3):208–14.PubMed
38.
Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.CrossRefPubMed
39.
Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.CrossRefPubMed
40.
Modell V, Knaus M, Modell F. An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia. Immunol Res. 2014;60(1):145–52.CrossRefPubMed
41.
Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22.CrossRefPubMedPubMedCentral
42.
Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292(14):1696–701.CrossRefPubMed
43.
Abolhassani H, Aghamohammadi A, Abolhassani F, Eftekhar H, Heidarnia M, Rezaei N. Health policy for common variable immunodeficiency: burden of the disease. J Investig Allergol Clin Immunol. 2011;21(6):454–8.PubMed
44.
Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–86.CrossRefPubMed
45.
Yong PF, Thaventhiran JE, Grimbacher B. “A rose is a rose is a rose,” but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol. 2011;111:47–107.CrossRefPubMed
46.
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.CrossRefPubMed
47.
Hovi T, Shulman LM, van der Avoort H, Deshpande J, Roivainen M, EM DEG. Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol Infect. 2012;140(1):1–13.CrossRefPubMed
48.
Hovi T, Paananen A, Blomqvist S, Savolainen-Kopra C, Al-Hello H, Smura T, et al. Characteristics of an environmentally monitored prolonged type 2 vaccine derived poliovirus shedding episode that stopped without intervention. PLoS One. 2013;8(7):e66849.CrossRefPubMedPubMedCentral
49.
Al-Hello H, Jorba J, Blomqvist S, Raud R, Kew O, Roivainen M. Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. J Virol. 2013;87(23):13076–80.CrossRefPubMedPubMedCentral
50.
Roivainen M, Blomqvist S, Al-Hello H, Paananen A, Delpeyroux F, Kuusi M, Hovi T. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill 2010, 15(19).
51.
World Health Organization. Vaccine-derived polioviruses detected worldwide, July 2009–March 2011. Wkly Epidemiol Rec. 2011;86(27):277–88.
52.
Li L, Ivanova O, Driss N, Tiongco-Recto M, de Silva R, Shahmahmoodi S, et al. Poliovirus excretion among persons with primary immune deficiency disorders: Summary of a seven-country study series. J Infect Dis. 2014;210 Suppl 1:S368–72.CrossRefPubMed
53.
Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch MA, Kew OM, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188:1845–52.CrossRefPubMed
54.
Driss N, Mellouli F, Ben Yahia A, Touzi H, Barbouche MR, Triki H, et al. Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency. J Clin Microbiol. 2014;52(9):3486–9.CrossRefPubMedPubMedCentral
55.
56.
Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World Population Prospects: The 2012 RevisionVolume I: Comprehensive tables. New York, 2013; Report No.: ST/ESA/SER.A/336.
57.
Minor P. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. Vaccine. 2009;27(20):2649–52.CrossRefPubMed
58.
Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51(1):61–70.CrossRefPubMed
59.
Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: Impact on the Global Polio Eradication Initiative. PLoS Pathog. 2015;11(8):e1005114.
60.
Tiongco-Recto M, Sumpaico MW, Dionisio-Capulong R, Kahn A-L, Sigrun R, Sutter RW. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in the Philippines. Acta Med Philipp. 2012;46(1):34–42.
61.
Triki H, Barbouche MR, Bahri O, Bejaoui M, Dellagi K. Community-acquired poliovirus infection in children with primary immunodeficiencies in Tunisia. J Clin Microbiol. 2003;41(3):1203–11.CrossRefPubMedPubMedCentral
62.
Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA. 1996;275(21):1639–45.CrossRefPubMed
63.
World Health Organization Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. J Infect Dis. 1997;175 Suppl 1:S215–27.CrossRef
64.
Más Lago P, Bravo JR, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, et al. Lesson from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ. 1994;72(2):221–5.PubMedPubMedCentral
65.
Savilahti E, Klemola T, Carlsson B, Mellander L, Stenvik M, Hovi T. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: Excretion of attenuated polio viruses is prolonged. J Clin Microbiol. 1988;8(2):89–94.
66.
Shahmahmoodi S, Mamishi S, Aghamohammadi A, Aghazadeh N, Tabatabaie H, Gooya MM, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995–2008. Emerg Infect Dis. 2010;16(7):1133–6.CrossRefPubMedPubMedCentral
Metadata
Title
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
Authors
Radboud J. Duintjer Tebbens
Mark A. Pallansch
Kimberly M. Thompson
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-1115-5

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue

Case report

Spontaneous remission of fully symptomatic visceral leishmaniasis

Research article

Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment

Research article

Spatial epidemiology and serologic cohorts increase the early detection of leprosy

Research article

Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe

Research article

Effect of early and current Helicobacter pylori infection on the risk of anaemia in 6.5-year-old Ethiopian children

Research article

“From me to HIV”: a case study of the community experience of donor transition of health programs
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits